Amicogen

Amicogen (China) Biopharm Co., Ltd., established in 2007, is a significant pharmaceutical entity operating within China's healthcare sector. The company specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and fine chemicals, adhering strictly to Good Manufacturing Practices (GMP). Amicogen's operations are underpinned by a robust commitment to environmental, health, and safety programs, evidenced by ISO9000, ISO14000, and OSHMS certifications. With a modern 2,000 square meter laboratory, Amicogen emphasizes innovation and collaborates with leading domestic and international R&D units. Its production lines are designed to meet cGMP standards, facilitating product registration with Drug Master Files (DMFs) and dossiers in numerous countries. The company maintains a dedicated Quality Inspection Center, staffed by highly trained QC personnel and equipped with specialized analytical instruments, ensuring excellent product quality and reputation.

Amicogen operates with a workforce of 500 - 1,000 employees and maintains 2 locations. The company's commitment to quality and compliance is further demonstrated by its Japan PMDA and Europe MRP certifications, alongside GMP certification for most products. Amicogen is actively engaged in developing new varieties and materials, focusing on psychotropic, metabolic, and cardiovascular drugs, and is researching high-quality treatments for Pulmonary Fibrosis. For insights into their operational structure and personnel, you can Meet Amicogen's team. The company provides comprehensive documentation for institutional supply and tender businesses in emerging markets, positioning itself as a reliable partner in the global pharmaceutical supply chain.

The company's revenue stands at $33.7M. Amicogen's strategic focus on advanced technology, stringent quality control, and continuous research and developmentView more...